A randomized trial to increase the efficiency of the prevention of contrast induced acute kidney injury. The Compass trial - The Compass Trial

eids Universitair Medisch Centrum0 个研究点目标入组 575 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•- patients with an eGFR (estimated glomerular filtration rate 30-45 ml/min)
•- patients with an eGFR 45-60 ml/min and diabetes mellitus (either type 1 or 2)
•- patients with an eGFR 45-60 ml/min and at least two of the following: peripheral artery disease, congestive heart failure, age > 75 years, anemia, contrastvolumes > 150 cc or the use of nephrotoxic medication
•- informed consent

•- eGFR < 30 ml/min
•- Age < 18 years
•- Patients with other intravenous contrast administrations (including intravenous contrast enhanced MRI) < 7 days of study CT-scan OR in 5 days following study CT-scan
•- pregnancy
•- renal transplantation in the last 3 years
•- previous participation to the Compass trial
•- dehydrated patients (systolic blood pressure < 100 mmHg)
•- proven instable renal function in the four weeks prior to randomisation (increase or decrease in serum creatinine > 20%)
•- known allergy for iodinated contrast media

发起方